Danish Synthetic Biology Drug Developer Octarine and British Clinical Research Organisation Clerkenwell Health Partner to Bring Innovative Psychedelics to Patients Post published:September 8, 2021 Post category:Press Release
Danish And British Startups Partner to Bring Innovative Psychedelics to Patients Post published:September 8, 2021 Post category:Press Release
Octarine Bio announces the expansion of its Scientific Advisory Board Post published:July 19, 2021 Post category:Press Release
Octarine Bio announces closing of extended seed round financing of $1.2 million USD with an uptick in valuation due to significant investor demand. Post published:March 11, 2021 Post category:Press Release
Nick Milne, Co-founder and CSO at Octarine Bio Post published:November 19, 2020 Post category:Interview
European synthetic biology company Octarine raises $1.8M USD in funding and enters pre-clinical studies with novel-improved- cannabinoid and psychedelic derivatives Post published:November 12, 2020 Post category:Press Release